What Cinaron Plus Treats: Main Uses and Benefits

Cinaron Plus is used for the short-term, symptomatic management of vertigo (a sensation of spinning or dizziness) of various causes in adults. This medicine may be used to address symptoms associated with certain cerebral and peripheral circulatory issues and disorders of balance. The combination is formulated to assist in relieving dizziness, nausea, and tinnitus (ringing in the ears), which can accompany these conditions.

The medicine's therapeutic domains include addressing symptoms related to cerebral vascular spasms and arteriosclerosis, as well as managing peripheral circulatory disorders and disorders of balance such as Meniere's syndrome and motion sickness. The expected benefit is the relief of distressing symptoms associated with these issues, which may contribute to patient comfort and stability.

The combination is intended for the treatment of vertigo symptoms of various origins in adults.

Intended to help relieve vertigo, nausea, and related discomforts.

---

Quick Fact: Symptom Relief for Vertigo and Dizziness

Cinaron Plus (Cinnarizine/Dimenhydrinate) eligibility is determined by official regulatory documents, which define specific populations who can and cannot use the medicine. The medicine is indicated only for use in adults, with the dosage for older adults being the same as for the general adult population.

---

Eligibility Restrictions

Population Status	Restrictions as per Regulatory Labeling
Contraindicated (Must Not Use)	Severe hepatic impairment; Severe renal impairment (creatinine clearance le 25 ml/min); Angle-closure glaucoma; Convulsions or seizure history; Suspicion of raised intracranial pressure; Alcohol abuse; Urine retention due to urethroprostatic disorders; Hypersensitivity to active substances or excipients.
Not Recommended	Children and adolescents under 18 years (safety not established). Pregnant women (safety not established). Breastfeeding women (active components are excreted in breast milk).
Use with Caution	Mild to moderate renal impairment; Patients with Parkinson's disease; Hypotensive patients; Conditions aggravated by anticholinergic effects (e.g., prostatic hypertrophy).

---

The medicine is subject to strict eligibility criteria defined by organ function status and specific comorbidities. The contraindications prohibit use in individuals with severe liver or kidney dysfunction and several central nervous system or anatomical conditions. Use is further restricted to adults, as safety and efficacy have not been established in pediatric or developmental populations.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cinaron Plus (Cinnarizine/Dimenhydrinate) primarily through two documented mechanisms: pharmacokinetic inhibition and pharmacodynamic potentiation.

Documented Pharmacodynamic Interactions

Co-administration with substances that depress the Central Nervous System (CNS depressants) is documented to result in the potentiation of sedative effects. This category includes medicines such as barbiturates, narcotic analgesics, and tranquillisers, as well as alcohol. Furthermore, the effects of Anticholinergics (e.g., atropine), Ephedrine, and medicines used to lower blood pressure (Anti-hypertensives) may be enhanced.

Pharmacokinetic and Exposure Interactions

The Dimenhydrinate component contains Diphenhydramine, which is classified as an inhibitor of the CYP2D6 metabolic enzyme. Co-administration with other medicines that are substrates for this enzyme (e.g., certain SSRIs, Tricyclic Antidepressants) may lead to officially documented increased plasma concentrations (exposure) of the co-administered drug.

Regulatory Restrictions and Cautions

This medicine is restricted for use with agents that prolong the QT interval of the ECG, such as Class Ia and Class III anti-arrhythmics. Co-administration with Aminoglycosidic Antibiotics carries a caution as the medicine may mask symptoms of ototoxicity. Additionally, its effects may mask the response of the skin to allergic skin tests, requiring a period of separation from testing procedures.

Dual Action on Histamine and Muscarinic Receptors

The components of Cinaron Plus exert their primary action in the central nervous system (CNS) by serving as antagonists at Histamine H1 receptors and Muscarinic cholinergic receptors. This dual receptor blockade primarily occurs within the vestibular nuclei in the brainstem and the Chemoreceptor Trigger Zone (CTZ). By interfering with histamine- and acetylcholine-mediated signaling in these areas, the drugs modulate the excitatory inputs that propagate the emetic reflex.

---

Modulating Ca^2+ Channels and Vestibular Signaling

Cinnarizine also modulates the peripheral vestibular apparatus (inner ear) by blocking L-type Ca^2+ channels. This inhibition of calcium ion influx into the sensory hair cells results in labyrinthine sedation, reducing cellular excitability and altering the transmission of signals from the peripheral vestibular system. Additionally, the Ca^2+ channel blockade promotes cerebral microcirculation in the inner ear.

---

Combined Systemic Effect

This medication utilizes combined central and peripheral signaling interference. The resulting effect is a comprehensive blockade of the entire vestibulo-emetic pathway, which involves both the modulation of peripheral sensory input and the suppression of central processing centers.

Cinaron Plus is administered by the oral route as a fixed-dose tablet, combining Cinnarizine 20 mg and Dimenhydrinate 40 mg. The standard dosing regimen for adults is one tablet taken three times daily (TID), which establishes the maximum recommended daily dose at three tablets. This consistent frequency is key to the product's standardized usage pattern.

---

Administration Conditions and Schedule

For proper administration, the tablet should be swallowed whole with a liquid and is directed to be taken after meals. This administration schedule is intended for short-term use, with the initial course of treatment set not to exceed a duration of four weeks. Continued administration beyond this time boundary necessitates a clinical re-evaluation by the prescribing authority.

---

Use in Specific Populations

Guidelines also define the scope for specific patient populations. Dosing for older adults follows the same regimen as the general adult population. The medicine is not recommended for children and adolescents under 18 years of age due to a lack of established safety and efficacy data. Additionally, contraindications apply to the usage in patients with severe impairment of kidney function or severe liver function, emphasizing distinct procedural constraints.

Cinaron Plus: Recent Clinical Evidence

---

Evidence Base for Symptoms of Vestibular Vertigo

Research has explored the combination’s application in adult populations experiencing symptoms of vestibular vertigo. This evidence base relies heavily on an analysis that brought together data from multiple short-term, randomized, and controlled clinical trials. These studies primarily focused on how symptoms change over time and were designed to evaluate patterns related to systemic or functional imbalance over defined time intervals.

In these trials, patient-reported outcomes describing perceived discomfort were closely monitored. Specifically, research examined changes in the Mean Vertigo Score (MVS)—a measure of symptom intensity—during the observation period. The findings describe patterns observed in the studies where MVS measurements showed differences when comparing the fixed-dose combination group to groups receiving placebo or individual monotherapies. This evidence provides insight into short-term symptom patterns in patient cohorts.

---

Research Focused on Specific Balance Disorders

Beyond general vertigo, studies explored the fixed combination's application in conditions characterized by fluctuating or episodic manifestations. Research examined patients with vertigo of peripheral vestibular origin, often utilizing active comparator treatments. Studies reported that the measurements of change in outcomes related to physical discomfort and associated symptoms varied when compared to the measurements in the placebo and single-ingredient groups over the short term.

For conditions involving periods of heightened symptoms, such as Ménière's disease, research was conducted over a longer, intermediate-term period of 12 weeks. In this specific trial setting, the combination was observed alongside an active reference drug. Findings indicate that the measured changes in vertigo symptom scores were reported to be statistically similar between the fixed combination group and the active reference drug group.

---

Evidence Gaps and Areas of Uncertainty

This summary highlights several key research limitations in the current evidence base. The follow-up durations were limited across the pivotal studies, meaning there is limited information available for long-term outcomes, and the certainty regarding sustained changes over extended periods remains low. Additionally, data for certain complex conditions, such as specific neurological or vascular-related causes of vertigo, are not extensive. Research provides context but not individual predictions, and evidence for specific patient subgroups remains limited.

Key Studies & References

1. Public Assessment Report Mutual Recognition Procedure (Arlevert 20 mg/40 mg tablets)
2. Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial

Common questions about Cinaron Plus (FAQ)

---

Q: What are the signs of an overdose of Cinaron Plus?

Official safety information indicates that symptoms of an overdose may include drowsiness and dizziness, as well as a lack of muscle coordination, known as ataxia. Other potential signs described in official safety information may include anticholinergic effects like dry mouth, facial flushing, increased heart rate, fever, headache, and difficulty urinating. Alterations in consciousness, vomiting, and convulsions have also been reported.

---

Q: How do I properly dispose of expired Cinaron Plus?

Regulatory guidance advises that this medicine must be disposed of according to local requirements and should not be placed in household trash or poured down the sink or toilet. When drug take-back programs are unavailable, official guidance often suggests following steps to make the medicine undesirable and placing it in a sealed container before disposal in the household trash, such as mixing it with coffee grounds or dirt.

---

Q: What is the specific purpose or indication of Cinaron Plus?

Cinaron Plus is officially indicated for the prophylaxis (prevention) and maintenance treatment of symptoms related to balance disorders. This includes symptoms such as vertigo, dizziness, nausea, and vomiting, which may be associated with conditions like vestibular irritability and Ménière's syndrome. The medicine is also indicated for the prevention of motion sickness.

---

Q: What other medicines should not be taken with Cinaron Plus?

Regulatory warnings state that caution is advised with Central Nervous System (CNS) depressants such as alcohol, narcotic pain medicines, and tranquilizers, as there is a potential for increased sedative effects. Official information also advises caution or restriction regarding co-administration with agents that prolong the QT interval. Furthermore, caution is advised with Aminoglycosidic Antibiotics, as Cinaron Plus has the potential to mask signs of ototoxicity (potential inner ear toxicity).

---

Q: What should I do if I have an allergic reaction to Cinaron Plus?

Official documents list hypersensitivity reactions (allergic reactions) as a rare but potential adverse effect. The medicine is contraindicated (must not be used) in patients who are known to be hypersensitive to the active substances or other components of the tablet. As with any medicine, if you experience signs of an allergic reaction, immediate medical assistance may be required.

How to Store and Dispose of Cinaron Plus

Cinaron Plus (cinnarizine and dimenhydrinate) tablets must be stored according to specific regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

Item	Official Regulatory Requirement
Temperature	Store the product below 30°C; some formulations require storage below 25°C.
Protection	Tablets must be protected from light and moisture and stored in a cool and dry place.
Handling	Do not freeze the tablets. Keep the medicine in its original container and keep it tightly closed.
Safety	It is mandatory to keep Cinaron Plus out of the sight and reach of children.

Disposal Instructions

Unused or expired Cinaron Plus must be disposed of in accordance with local requirements. The medicine must not be thrown away via wastewater or placed in household trash, as specified by official labeling.